A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

Inclusion Criteria:

• Previously diagnosed with histologically or cytologically confirmed unresectableStage IV (metastatic) non-small cell lung cancer (NSCLC) (any histology)

• May have: definitively, locally treated brain metastases that are clinically stableand asymptomatic for greater than (>) 2 weeks and who are off or receiving low-dosecorticosteroid treatment (less than or equal to [<=]10 milligrams (mg) prednisone orequivalent) for at least 2 weeks prior to start of study treatment

• May have a prior malignancy (other than the disease under study) the natural historyor treatment of which is unlikely to interfere with any study endpoints of safety orthe efficacy of the study treatment(s)

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• A participant of childbearing potential must have a negative serum pregnancy test atscreening and within 72 hours of the first dose of study treatment and must agree tofurther serum or urine pregnancy tests during the study

Exclusion Criteria:

• Medical history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, orhas current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled outby imaging at screening

• Participant has impairment of the gastrointestinal function that could affectabsorption of capmatinib or is unable or unwilling to swallow tablets

• Participant has symptomatic central nervous system (CNS) metastases which areneurologically unstable or have required increasing doses of steroids >10 mgprednisone or equivalent within the 2 weeks prior to study entry to manage CNSsymptoms

• Participant has uncontrolled tumor-related pain: Symptomatic lesions amenable topalliative radiotherapy (example, bone metastases, or metastases causing nerveimpingement) should be treated more than 7 days prior to the administration of thefirst study treatment